Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Pipeline Developments & Deals by PNB Vesper

All Data

Filters

refresh

×

FILTER DATA :

Therapeutic Area

Study Phase

Country

News Type

Company

refresh

Companies By Therapeutic Area

Development Status

PNB Vesper

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

PNB Vesper begins GPP-Baladol clinical trials in COVID-19 patients at BJ Medical College & Sasoon General Hospital Pune

Contact the Supplier

Lead Product(s): GPP-Baladol

Therapeutic Area: Infections and Infectious Diseases Product Name: PNB-001

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 27, 2020

Details:

The effect of PNB 001 (GPP-Baladol) will be compared with dexamethasone, currently the most used medication for COVID-19 treatment. The molecule has already been patented and the related IPRs have been secured by PNB VESPER in the US, Europe and rest of the world.